You are here:
| Reference : Les traitements biologiques en rhumatologie |
| Scientific journals : Article | |||
| Human health sciences : Rheumatology | |||
| http://hdl.handle.net/2268/72447 | |||
| Les traitements biologiques en rhumatologie | |
| French | |
| [en] Biological therapies in rheumatology | |
Von Frenckell, Christian  [Université de Liège - ULg > > Rhumatologie >] | |
| Malaise, Michel [Université de Liège - ULg > Département des sciences cliniques > Rhumatologie >] | |
| 2009 | |
| Revue Médicale de Liège | |
| Hopital de Baviere | |
| 64 | |
| 5-6 | |
| 293-300 | |
| National | |
| 0370-629X | |
| Liège | |
| Belgique | |
| [en] Antibodies, Monoclonal ; Antirheumatic Agents ; Immunoglobulin Fab Fragments ; Immunoglobulin G ; Polyethylene Glycols ; Receptors, Tumor Necrosis Factor ; adalimumab ; golimumab ; infliximab | |
| [en] Biological therapies consisting of monoclonal antibodies and soluble receptors
have revolutionized the care of rheumatologic patients. These therapies ensued from a better understanding of the physiopathology of rheumatologic disorders. Most of the latter have been concerned: rheumatoid arthritis (for about 10 years), psoriatic arthritis and ankylosing spondilitys (for more or less five years). Rheumatology was among the first disciplines to make use of these advances; it continues to benefit from the results of intense research efforts. These developments request from clinicians an increased expertise in immunology. | |
| Researchers ; Professionals ; Students ; General public | |
| http://hdl.handle.net/2268/72447 | |
| http://www.rmlg.ulg.ac.be |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
